Apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN study.
Japan
androgen deprivation therapy
apalutamide
castration-sensitive prostate cancer
metastatic
Journal
International journal of urology : official journal of the Japanese Urological Association
ISSN: 1442-2042
Titre abrégé: Int J Urol
Pays: Australia
ID NLM: 9440237
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
26
02
2020
accepted:
29
10
2020
pubmed:
10
12
2020
medline:
28
4
2021
entrez:
9
12
2020
Statut:
ppublish
Résumé
To evaluate the efficacy and safety of apalutamide + androgen deprivation therapy versus androgen deprivation therapy alone in Japanese patients with metastatic castration-sensitive prostate cancer from the phase 3, randomized, global TITAN study. Men with metastatic castration-sensitive prostate cancer randomly (1:1) received 240 mg apalutamide + androgen deprivation therapy or matching placebo + androgen deprivation therapy. The primary efficacy endpoints were radiographic progression-free survival and overall survival. Secondary efficacy endpoints were time to cytotoxic chemotherapy, pain progression, chronic opioid use, and skeletal-related events. Safety was also assessed. Of the 1052 patients included in the TITAN study, 51 (4.85%) were Japanese (apalutamide group, n = 28; placebo group, n = 23). In all, 81.8% of patients in the apalutamide and 71.8% in the placebo group did not experience radiographic progression or death, and the hazard ratio for radiographic progression-free survival favored treatment with apalutamide (hazard ratio 0.712, 95% confidence interval 0.205-2.466; P = 0.59). At 24 months, 85.7% of patients in the apalutamide group and 81.5% in the placebo group were alive, and the hazard ratio for overall survival favored apalutamide (hazard ratio 0.840, 95% confidence interval 0.210-3.361; P = 0.805). In the interim analysis, the median radiographic progression-free survival and overall survival were not reached in the apalutamide group and time to cytotoxic chemotherapy was delayed following apalutamide treatment. The safety profile of apalutamide in the Japanese subpopulation was comparable with that of the global population, except for skin rash. The results of the present analyses suggest that apalutamide + androgen deprivation therapy in Japanese patients had favorable efficacy compared with androgen deprivation therapy alone, and these findings are comparable to those in the overall population. Apalutamide + androgen deprivation therapy can be considered as one of the therapeutic options for a broad spectrum of metastatic castration-sensitive prostate cancer regardless of prior treatment and disease extent in Japanese patients.
Substances chimiques
Androgen Antagonists
0
Thiohydantoins
0
apalutamide
0
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
280-287Subventions
Organisme : Janssen Research & Development, LLC
Organisme : Janssen Pharmaceutical K.K
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 The Japanese Urological Association.
Références
Chen R, Ren S, Yiu MK et al. Prostate cancer in Asia: a collaborative report. Asian J. Urol. 2014; 1: 15-29.
Ito K. Prostate cancer in Asian men. Nat. Rev. Urol. 2014; 11: 197-212.
Kimura T, Egawa S. Epidemiology of prostate cancer in Asian countries. Int. J. Urol. 2018; 25: 524-31.
Cooperberg MR, Hinotsu S, Namiki M et al. Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J. Clin. Oncol. 2009; 27: 4306.
Fitzpatrick JM, Bellmunt J, Fizazi K et al. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel. Eur. J. Cancer 2014; 50: 1617-27.
Hellerstedt BA, Pienta KJ. The current state of hormonal therapy for prostate cancer. CA Cancer J. Clin. 2002; 52: 154-79.
Yamaoka M, Hara T, Kusaka M. Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer. Clin. Cancer Res. 2010; 16: 4319-24.
Fizazi K, Tran NamPhuong, Fein L et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 2017; 377: 352-60.
Fukasawa S, Suzuki H, Kawaguchi K et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naïve prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, Phase 3 study. Jpn. J. Clin. Oncol. 2018; 48: 1012-21.
Gravis G, Boher J-M, Joly F et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur. Urol. 2016; 70: 256-62.
Gravis G, Fizazi K, Joly F et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013; 14: 149-58.
James ND, Sydes MR, Clarke NW et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016; 387: 1163-77.
Satoh T, Arai G, Uemura H et al. The efficacy and safety of apalutamide for Japanese patients with NM-CRPC: Sub-analysis of randomized, multicenter, double-blind, phase III study. 107th Annual meeting of Japanese Urological Association, Nagoya Congress Center Nagoya Gakuin University, 2019.
The Janssen Pharmaceutical Companies of Johnson & Johnson. Janssen Announces European Commission Approval of Erleada® (Apalutamide) for non-metastatic castration-resistant prostate cancer patients who are at high risk of developing metastatic disease. 2019. [Cited 23 Nov 2019.] Available from URL: https://johnsonandjohnson.gcs-web.com/static-files/168b7247-52c3-4b28-8531-3d7f8e38010a
MHLW approval of ERLEADA (apalatumide) 60 mg tables for the treatment of castration-resistant prostate cancer without distant metastases. 2019. [Cited 23 Nov 2019.] Available from URL: https://www.janssen.com/japan/press-release/20190326
Chi KN, Agarwal N, Bjartell A et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N. Engl. J. Med. 2019; 381: 13-24.
Smith MR, Saad F, Chowdhury S et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N. Engl. J. Med. 2018; 378: 1408-18.
Namiki M, Akaza H, Lee SE et al. Prostate Cancer Working Group report. Jpn. J. Clin. Oncol. 2010; 40(Suppl 1): i70-i75.
Fukasawa S, Suzuki H, Kawaguchi K et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, Phase 3 study. Jpn. J. Clin. Oncol. 2018; 48: 1012-21.
Fukagai T, Namiki TS, Carlile RG, Yoshida H, Namiki M. Comparison of the clinical outcome after hormonal therapy for prostate cancer between Japanese and Caucasian men. BJU Int. 2006; 97: 1190-3.
Namiki M, Ueno S, Kitagawa Y, Fukagai T, Akaza H. Effectiveness and adverse effects of hormonal therapy for prostate cancer: Japanese experience and perspective. Asian J. Androl. 2012; 14: 451-7.
Fukagai T, Shimada M, Yoshida H, Namiki T, Carlile RG. Clinical-pathological comparison of clinical prostate cancer between Japanese Americans in Hawaii and Japanese living in Japan. Int. J. Androl. 2000; 23(Suppl 2): 43-4.